Search

Displaying results 7831 - 7840 of 8573 in total
  1. Drug

    Izilendustat

    go.drugbank.com/drugs/DB21532
    Experimental

    Izilendustat has a monoisotopic molecular weight of 433.18 Da.

  2. Drug

    Civorebrutinib

    go.drugbank.com/drugs/DB21641
    Experimental

    Civorebrutinib has a monoisotopic molecular weight of 463.15 Da.

  3. Drug

    Poractant alfa

    go.drugbank.com/drugs/DB09113
    ApprovedInvestigational

    Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada.

  4. Drug

    Penbutolol

    go.drugbank.com/drugs/DB01359
    ApprovedInvestigationalWithdrawn

    Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug.

  5. Drug

    Magnesium cation

    go.drugbank.com/drugs/DB01378
    ApprovedInvestigationalNutraceuticalWithdrawn

    When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend

  6. Drug

    Hexobarbital

    go.drugbank.com/drugs/DB01355
    Experimental

    A barbiturate that is effective as a hypnotic and sedative.

  7. Drug

    Aminomethylbenzoic acid

    go.drugbank.com/drugs/DB13244
    Experimental

    Aminomethylbenzoic acid may be useful as an antifibrinolytic agent [A174994].

  8. Drug

    Aceprometazine

    go.drugbank.com/drugs/DB01615
    Experimental

    Aceprometazine is a is a drug with neuroleptic and anti-histamine properties. Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine.

  9. Drug

    Furvina

    go.drugbank.com/drugs/DB16547
    Experimental

    Furvina is marketed in Cuba as Dermofural®, an ointment containing G1 as the only active principle ingredient. It is used to treat dermatological infections.[A228063]

  10. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection.